Trans-Diamminedichloroplatinum (II) Is Not an Antitumor Drug: Why?

Abstract : The clinical activity of the antitumor drug cis-diamminedichloroplatinum(II) (cis-DDP) is thought to be related to its ability to form bifunctional lesions in DNA. trans-Diamminedichloroplatinum(II) (trans-DDP), the stereoisomer of cis-DDP, is clinically ineffective, although it forms bifunctional cross-links in the in vitro reaction with DNA1–4. A question still unsolved is why only cis-DDP is an antitumor drug.
Complete list of metadatas
Contributor : Marc Boudvillain <>
Submitted on : Friday, April 12, 2019 - 11:24:48 AM
Last modification on : Wednesday, April 24, 2019 - 10:49:50 AM


  • HAL Id : hal-02097755, version 1



Marc Boudvillain, Dalbiès R., Leng M.. Trans-Diamminedichloroplatinum (II) Is Not an Antitumor Drug: Why?. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, 2, Plenum Press, New'Tork, USA, pp.17-25, 1996. ⟨hal-02097755⟩



Record views